The Alliance of U.S. Startups and Inventors for Jobs (USIJ) highlights a new op-ed by Executive Director Chris Israel, published in RealClearHealth, titled “Don’t Import Foreign Price Controls: Export American Innovation Instead.”
In the piece, Mr. Israel cautions that proposals to adopt “Most Favored Nation” (MFN) drug pricing—tying U.S. medicine prices to the artificially low levels set abroad—would undermine the patent protections and investment environment that enable American startups to drive global biotechnology innovation. He emphasizes that over half of new U.S. drug approvals originate from startups and small companies, which rely heavily on venture capital sustained by strong intellectual property rights.
“MFN pricing would upend that promise by tethering U.S. drug prices to the artificially low prices in countries that don’t share our investment burden — and in some cases, our values.”
Instead of replicating failed foreign models, Mr. Israel urges policymakers to strengthen U.S. patent law, hold foreign governments accountable for IP violations, and ensure startups are represented in trade and innovation policy discussions.